Praxis stock surges on late-stage trial win (PRAX:NASDAQ)

Praxis Precision Medicines (NASDAQ:PRAX) added ~134% in the premarket on Thursday after the Boston-based biotech announced that its experimental therapy ulixacaltamide succeeded in two late-stage trials for essential tremor, the commonest type of movement disorder. Based on data from its ...